Thiogenesis Therapeutics Corp (TTI)

Thiogenesis Appoints Dr. Gilad Aharon to Its Board of DirectorsJune 17, 2026 8:00 AM
NewsfileSan Diego, California--(Newsfile Corp. - June 17, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation cysteamine-based therapies for rare diseases, including cystinosis and primary mitochondrial diseases, today announced the appointment of Gilad Aharon, PhD, to its Board of Directors. Dr. Aharon is a Co-Founder and Portfolio Manager at Rosalind Advisors, Inc., a Toronto-based life sciences institutional investor. The appointment follows Rosalind Advisors' investment in Thiogenesis' recently completed, non-brokered private placement. Dr. Aharon holds a Ph.D. in Biophysics and Molecular Biology from the University of Toronto. "Gil brings significant experience and depth of insight in the life sciences sector, and we look forward to working together in advancing TTI-0102," said Patrice Rioux, Chief Executive Officer of Thiogenesis.Dr. Aharon added, "Thiogenesis has taken a disciplined approach to developing TTI-0102, with a clear focus on its late-stage cystinosis program while continuing development in primary mitochondrial disease, including Leigh syndrome spectrum disorders. By joining the board, Rosalind is committing to support the Company's execution on a clear set of near-term clinical and regulatory objectives addressing areas of high unmet medical needs." The Company also wishes to announce, that further to its news release of June 3, 2026, the TSX Venture Exchange has issued its final acceptance for the Company's previously announced non-brokered private placement. About Rosalind Advisors, Inc.Rosalind Advisors, Inc. is a Toronto-based Investment Manager founded in 2006 that specializes in the biotechnology and life sciences sectors. About ThiogenesisBased in San Diego, California, Thiogenesis Therapeutics Corp. (TSXV: TTI) (OTCQX: TTIPF) is a clinical-stage biotechnology company developing TTI-0102, a novel controlled-release cysteamine prodrug designed to improve tolerability and dosing relative to existing therapies. The Company is focused on TTI-0102 in nephropathic cystinosis, where it is in late-stage development, and is also advancing research and clinical work in primary mitochondrial diseases, initially focused on Leigh syndrome spectrum disorders.For further information, please contact:Brook Riggins, Director and CFO
Email: info @vingForward-Looking StatementsSome statements contained in this news release are forward-looking information within the meaning of Canadian securities laws. Generally, forward-looking information can be identified by the use of forward-looking terminology such as plans, expects, is expected, budget, scheduled, estimates, forecasts, intends, anticipates, believes or variations of such words and phrases including negative or grammatical variations or statements that certain actions, events or results may, could, would, might or will be taken, occur or be achieved or the negative connotation thereof. Investors are cautioned that forward-looking information is inherently uncertain and involves risks, assumptions and uncertainties that could cause actual facts to differ materially. There can be no assurance that future developments affecting the Company will be those anticipated by management. The forward-looking information contained in this press release constitutes management's current estimates, as of the date of this press release, with respect to the matters covered thereby. We expect that these estimates will change as new information is received. While we may elect to update these estimates at any time, we do not undertake to update any estimate at any particular time or in response to any event.Neither the TSX Venture Exchange nor its Regulation Services Provider as that term is defined in the policies of the TSX Venture Exchange nor the OTC Markets Group Inc. accepts responsibility for the adequacy or accuracy of this news release.This news release is not an offer of securities for sale in the United States. The securities may not be offered or sold in the United States absent registration or an exemption from registration under U.S. Securities Act of 1933, as amended - the U.S. Securities Act. The Company has not registered and will not register the securities under the U.S. Securities Act. The Company does not intend to engage in a public offering of their securities in the United States.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301783 Original: Thiogenesis Appoints Dr. Gilad Aharon to Its Board of Directors

Thiogenesis Closes Oversubscribed Non-Brokered Private Placement for Gross Proceeds of C$9.07 MillionJune 3, 2026 6:00 AM
NewsfileSan Diego, California--(Newsfile Corp. - June 3, 2026) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing a next-generation cysteamine-based therapy for rare diseases, is pleased to announce that, further to its news releases of May 11 and June 1, 2026, it has completed an oversubscribed non-brokered private placement (the "Offering") through the issuance of 18,143,700 common shares (the "Offered Shares") at a price of C$0.50 per Offered Share for gross proceeds of C$9,071,850. All securities issued in connection with the Offering are subject to a four-month plus one day hold period ending October 2, 2026. The Offering has received conditional acceptance from the TSX Venture Exchange and remains subject to final acceptance. In connection with the Offering, the Company paid certain qualified finders: (i) a cash finder's fee equal to 7% of the gross proceeds raised from subscribers introduced by such finders, and (ii) non-transferable finder's options equal to 7% of the Offered Shares issued to such subscribers. Each finder's option entitles the holder to acquire one common share at a price of C$0.60 per share for a period of three years. In total, the Company paid C$561,529.50 in finder's fees and issued 780,059 finder's options. An independent director of the Company participated in the Offering and acquired 150,000 Offered Shares. The issuance to such insider constitutes a "related party transaction" under Multilateral Instrument 61-101 ("MI 61-101"). The Company relied on exemptions from the formal valuation and minority shareholder approval requirements in accordance with MI 61-101 and applicable policies of the TSX Venture Exchange. Net proceeds from the Offering will be used to advance the clinical development of TTI-0102, including an investigator-initiated study in cystinosis and a Phase 2a clinical study in Leigh syndrome spectrum, together with formulation and manufacturing activities, regulatory engagement, and general working capital and corporate purposes. In connection with the Offering, the Company engaged Bloom Burton Securities Inc. as a financial and strategic advisor on a non-exclusive basis. Bloom Burton provided advisory services to the Company in respect of the oversubscribed Offering. The Company paid Bloom Burton Securities Inc. a cash fee of C$50,000 for its advisory services. Bloom Burton Securities Inc. does not own any securities of the Company.About ThiogenesisBased in San Diego, California, Thiogenesis Therapeutics Corp. (TSXV: TTI) (OTCQX: TTIPF) is a clinical-stage biotechnology company developing TTI-0102, a novel once-daily, controlled-release cysteamine prodrug designed to improve tolerability and dosing relative to existing therapies. The Company is focused on TTI-0102 in nephropathic cystinosis, where it is in late-stage development. The Company is also planning to conduct a Phase 2a clinical study in Leigh syndrome spectrum disorders.For further information, please contact:Brook Riggins, Director and CFO
Email: info @vingForward Looking StatementsSome statements contained in this news release are forward-looking information within the meaning of Canadian securities laws. Generally, forward-looking information can be identified by the use of forward-looking terminology such as plans, expects, is expected, budget, scheduled, estimates, forecasts, intends, anticipates, believes or variations of such words and phrases including negative or grammatical variations or statements that certain actions, events or results may, could, would, might or will be taken, occur or be achieved or the negative connotation thereof. Investors are cautioned that forward-looking information is inherently uncertain and involves risks, assumptions and uncertainties that could cause actual facts to differ materially. There can be no assurance that future developments affecting the Company will be those anticipated by management. The forward-looking information contained in this press release constitutes management's current estimates, as of the date of this press release, with respect to the matters covered thereby. We expect that these estimates will change as new information is received. While we may elect to update these estimates at any time, we do not undertake to update any estimate at any particular time or in response to any event.Neither the TSX Venture Exchange nor its Regulation Services Provider as that term is defined in the policies of the TSX Venture Exchange nor the OTC Markets Group Inc. accepts responsibility for the adequacy or accuracy of this news release.This news release is not an offer of securities for sale in the United States. The securities may not be offered or sold in the United States absent registration or an exemption from registration under U.S. Securities Act of 1933, as amended - the U.S. Securities Act. The Company has not registered and will not register the securities under the U.S. Securities Act. The Company does not intend to engage in a public offering of their securities in the United States.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/299857 Original: Thiogenesis Closes Oversubscribed Non-Brokered Private Placement for Gross Proceeds of C$9.07 Million

Thiogenesis Upsizes Non-Brokered Private Placement of Common SharesJune 1, 2026 2:49 PM
NewsfileSan Diego, California--(Newsfile Corp. - June 1, 2026) - Thiogenesis Therapeutics Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing a next-generation cysteamine-based therapy for rare diseases, today announced that, due to strong investor demand, it has increased the size of its previously announced non-brokered private placement (the "Offering") (see the Company's news release dated May 11, 2026) from 16 million to approximately 18 million common shares at a price of $0.50 per Common Share of the Company for gross proceeds of approximately $9 million.The Offering has received conditional acceptance from the TSX Venture Exchange. Closing is expected to occur later this week, subject to final acceptance by the TSX Venture Exchange and customary closing conditions.Net proceeds from the Offering will be used to advance the clinical development of TTI-0102, including an investigator-initiated study in cystinosis and a Phase 2a clinical study in Leigh syndrome spectrum, together with formulation and manufacturing activities, regulatory engagement, and general working capital and corporate purposes. About ThiogenesisBased in San Diego, California, Thiogenesis Therapeutics Corp. (TSXV: TTI) (OTCQX: TTIPF) is a clinical-stage biotechnology company developing TTI-0102, a novel controlled-release cysteamine prodrug designed to improve tolerability and dosing relative to existing therapies. The Company is focused on TTI-0102 in nephropathic cystinosis, where it is in late-stage development, and is also advancing research and clinical work in primary mitochondrial diseases, initially focused on Leigh syndrome spectrum disorders.For further information, please contact:Brook Riggins, Director and CFO
Email: info @vingForward-Looking StatementsSome statements contained in this news release are forward-looking information within the meaning of Canadian securities laws. Generally, forward-looking information can be identified by the use of forward-looking terminology such as plans, expects, is expected, budget, scheduled, estimates, forecasts, intends, anticipates, believes or variations of such words and phrases including negative or grammatical variations or statements that certain actions, events or results may, could, would, might or will be taken, occur or be achieved or the negative connotation thereof. Investors are cautioned that forward-looking information is inherently uncertain and involves risks, assumptions and uncertainties that could cause actual facts to differ materially. There can be no assurance that future developments affecting the Company will be those anticipated by management. The forward-looking information contained in this press release constitutes management's current estimates, as of the date of this press release, with respect to the matters covered thereby. We expect that these estimates will change as new information is received. While we may elect to update these estimates at any time, we do not undertake to update any estimate at any particular time or in response to any event.Neither the TSX Venture Exchange nor its Regulation Services Provider as that term is defined in the policies of the TSX Venture Exchange nor the OTC Markets Group Inc. accepts responsibility for the adequacy or accuracy of this news release.This news release is not an offer of securities for sale in the United States. The securities may not be offered or sold in the United States absent registration or an exemption from registration under U.S. Securities Act of 1933, as amended - the U.S. Securities Act. The Company has not registered and will not register the securities under the U.S. Securities Act. The Company does not intend to engage in a public offering of their securities in the United States.NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/299682 Original: Thiogenesis Upsizes Non-Brokered Private Placement of Common Shares

Thiogenesis Announces Non-Brokered Private PlacementMay 11, 2026 9:00 AM
NewsfileSan Diego, California--(Newsfile Corp. - May 11, 2026) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing a next-generation cysteamine-based therapy for rare diseases, announced today that it will undertake a non-brokered private placement (the "Offering") of up to 16,000,000 common shares of the Company ("Offered Shares") at a price of $0.50 per Common Share for gross proceeds of $8 million.This Offering is subject to the approval of the TSX Venture Exchange (the "Exchange"). The Company anticipates closing of the Offering by the end of May subject to receipt of all necessary regulatory approvals. Upon issuance, the Offered Shares will be subject to a four-month and one day hold period pursuant to securities laws in Canada and, where applicable, Exchange policies.In connection with the Offering, the Company may pay finder's fees to eligible persons in compliance with applicable securities laws and Exchange policies. The proceeds of the financing will be used to support the clinical development of TTI-0102, including an investigator-initiated study in cystinosis and a Phase 2 clinical study in Leigh syndrome, together with formulation and manufacturing activities, regulatory engagement, and general working capital and corporate purposes.About ThiogenesisBased in San Diego, California, Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) is a clinical-stage biotechnology company developing TTI-0102, a novel controlled-release cysteamine prodrug designed to offer improved tolerability and dosing compared with existing therapies. The company is advancing TTI-0102 toward a pivotal Phase 3 clinical trial in nephropathic cystinosis and is supporting clinical development in inherited mitochondrial diseases, following completion of a Phase 2 programme in MELAS and the initiation of a Phase 2 clinical study in Leigh syndrome.For further information, please contact:Brook Riggins, Director and CFO
Email: info @vingForward Looking StatementsThis news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as forward-looking statements) within the meaning of Canadian securities laws including, without limitation, statements with respect to: the Company undertaking a non-brokered private placement to raise up to $8 million at a price of $0.50 per Common Share; the Offering being subject to the approval of the TSX Venture Exchange; the Company anticipating closing the Offering as soon as practicable; that the Shares (if sold) will be subject to a four-month and one day hold period; that the Company may pay finder's fees in connection with the Offering; the proceeds (if Shares are sold) from the Offering will be used for MELAS clinical trial expenses, the creation and purchase of additional TTI-0102 for future clinical trials. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur. Although the Company believes that the expectations reflected in the forward-looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions, or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the Company's actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.This press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein have not been and will not be registered under the Securities Act of 1933, as amended (the "Securities Act"), or with any securities regulatory authority of any state or other jurisdiction in the United States, and may not be offered or sold, directly or indirectly, within the United States or to, or for the account or benefit of, U.S. persons, as such term is defined in Regulation S under the Securities Act ("Regulation S"), except pursuant to an exemption from or in a transaction not subject to the registration requirements of the Securities Act.NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICESTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/296807 Original: Thiogenesis Announces Non-Brokered Private Placement

Thiogenesis Therapeutics to Present at 2026 Bloom Burton & Co. Healthcare Investor ConferenceApril 16, 2026 9:00 AM
NewsfileSan Diego, California--(Newsfile Corp. - April 16, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biopharmaceutical company developing sulfur-based prodrugs designed as precursors to thiol-active compounds such as cysteamine, today announced that management will present at the 2026 Bloom Burton & Co. Healthcare Investor Conference, taking place in Toronto, Canada.Presentation Details:Date: Wednesday, April 22, 2026
Time: 1:30-2:00 p.m. ET
Location: Room 104 A
Presenters: Brook Riggins, CFA, Director and Chief Financial Officer, and Patrice Rioux, M.D., Ph.D., Chief Executive Officer and Co-FounderThe presentation will provide an overview of Thiogenesis Therapeutics and its clinical-stage development programs, including its late-stage lead program in nephropathic cystinosis and expansion into mitochondrial disease indications, including Leigh syndrome.About Bloom Burton & Co.Bloom Burton & Co. is a leading Canadian investment bank focused exclusively on the healthcare sector. The firm's annual healthcare investor conference brings together public and private healthcare companies with institutional investors and industry participants to discuss clinical progress, emerging science and investment opportunities.About Thiogenesis TherapeuticsThiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) is a clinical-stage biopharmaceutical company with operations based in San Diego, California. The Company is developing sulfur-containing prodrugs designed as precursors to previously approved thiol-active compounds, with a focus on serious pediatric diseases with significant unmet medical need. Thiogenesis' lead product candidate, TTI-0102, is a late-stage program being advanced toward a Phase 3 clinical trial in nephropathic cystinosis. In addition, the Company is pursuing the potential expansion of its thiol-based platform into mitochondrial diseases, including Leigh syndrome and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke (MELAS), as well as other metabolic indications.For further information, please contact:Brook Riggins, Director and CFO
Email: info @vingForward Looking StatementsThis news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as forward-looking statements) within the meaning of Canadian securities laws including, without limitation, statements with respect to the future investments by the Company. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur. Although the Company believes that the expectations reflected in the forward-looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions, or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the Company's actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTC Markets Group Inc. (OTCQX: OTCM) accepts responsibility for the adequacy or accuracy of this news release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/292731
Original: Thiogenesis Therapeutics to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference

Posted on behalf of Thiogenesis Therapeutics, Corp. – Today, Thiogenesis Therapeutics (TTI.v TTIPF) announced a new investigator-initiated study of its lead drug, TTI-0102, in nephropathic cystinosis, to support dose optimisation and inform TTI's planned Phase 3 pivotal trial under the FDA’s 505(b)(2) pathway🤝💥

Full update here: https://cdn.prod.website-files.com/6324f3c1cd40a857e0ea27a4/6980ef6f54d79879d35e8e2f_TTI%20NR%20260202%20Cystinosis%20Investigator%20Study.pdf

Thiogenesis Therapeutics Announces Investigator-Initiated Study in Nephropathic Cystinosis and Provides Program UpdateFebruary 2, 2026 9:00 AM
NewsfileSan Diego, California--(Newsfile Corp. - February 2, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation sulfur-based prodrugs for rare pediatric diseases, today provided an update on its nephropathic cystinosis program and announced a new investigator-initiated study (IIS) collaboration with Dr. Larry Greenbaum, a recognized global leader in cystinosis research, at Emory University and Children's Healthcare of Atlanta.The IIS will evaluate Thiogenesis' lead product candidate, TTI-0102, a next-generation cysteamine-based prodrug, in patients with nephropathic cystinosis to further characterize once-daily dosing, tolerability, and white blood cell (WBC) cystine control across a representative patient population. Data generated from the study are expected to support dose optimization and inform the Company's planned Phase 3 pivotal program.Dr. Greenbaum serves as Chief of Pediatric Nephrology at Children's Healthcare of Atlanta and Professor of Pediatrics at Emory University School of Medicine. He has served as a principal investigator in multiple cystinosis clinical programs and sits on the scientific and medical advisory boards of leading cystinosis patient organizations. His clinical site previously participated in the development of delayed-release cysteamine therapy, providing direct continuity with current standards of care.TTI-0102: Designed to Address Limitations of Current Cysteamine TherapiesCystinosis requires lifelong cystine-depleting therapy; however, currently approved cysteamine products, Cystagon® and Procysbi®, are associated with frequent dosing, gastrointestinal intolerance, and adherence challenges that can limit long-term disease control.TTI-0102 is a novel cysteamine-based disulfide prodrug designed to deliver sustained cysteamine exposure with lower peak plasma concentrations, enabling the potential for once-daily oral dosing.Across clinical development programs, TTI-0102 has demonstrated:Sustained 24-hour cysteamine exposure with weight-based dosingLower peak-related gastrointestinal adverse events compared to fixed dosing approachesTarget cysteamine exposure achieved at approximately half the daily cysteamine base dose used with existing therapiesA dual biological profile supporting cystine depletion and intracellular antioxidant pathways, including glutathione and taurine, consistent with cysteamine biologyImportantly, dosing and tolerability insights from Thiogenesis' Phase 2 MELAS program have directly informed cystinosis development strategy, supporting refined, weight-based dosing designed to optimize exposure while minimizing adverse events.Phase 3 Development and Regulatory PathwayThiogenesis is preparing to initiate scale-up of the manufacturing process for a newly patented salt formulation of TTI-0102, which is required to produce sufficient clinical material to support formal stability testing. Stability testing of the new salt formulation is expected to be conducted in parallel with finalization of the Company's Investigational New Drug (IND) application for cystinosis.Upon completion of these activities, the Company plans to initiate a Phase 3 pivotal, non-inferiority study comparing TTI-0102 to an approved cysteamine therapy under FDA's 505(b)(2) regulatory pathway.The planned Phase 3 study is expected to leverage:WBC cystine concentration as a well-validated surrogate endpointA non-inferiority design versus standard-of-care cysteamine therapySimplified dosing and improved tolerability as key secondary and patient-reported outcomesGiven the well-established regulatory precedent in cystinosis and the sensitivity of WBC cystine as a biomarker, Thiogenesis believes this approach represents an efficient and well-defined path toward registration."This investigator-initiated study allows us to evaluate TTI-0102 in a real-world cystinosis population under the leadership of one of the most experienced investigators in the field," said Dr. Patrice Rioux, Chief Executive Officer of Thiogenesis Therapeutics. "We have spent years working alongside the cystinosis community and deeply understand the burden current therapies place on patients and families. TTI-0102 was engineered to simplify daily treatment while maintaining the biochemical efficacy patients depend on, and we are excited about its potential to offer a better-tolerated option that could meaningfully improve adherence and quality of life."About Nephropathic CystinosisNephropathic cystinosis is a rare, autosomal recessive lysosomal storage disorder caused by mutations in the CTNS gene, leading to toxic intracellular cystine accumulation and progressive multi-organ damage. Without disease-modifying therapy, patients develop renal Fanconi syndrome, growth failure, and progression to end-stage renal disease.Cystinosis affects an estimated 2,000–2,500 patients worldwide, representing a global market opportunity of over $300 million. While cysteamine therapy slows disease progression, tolerability and adherence challenges remain a significant unmet medical need. About TTI-0102TTI-0102 is a sulfur-based disulfide prodrug consisting of two cysteamine molecules and one molecule of pantothenic acid (Vitamin B5). Following oral administration, metabolic activation delivers sustained cysteamine exposure with reduced peak-related toxicity, enabling once-daily dosing. TTI-0102 is currently in clinical development for MELAS, Leigh syndrome, pediatric MASH, and nephropathic cystinosis.About Thiogenesis TherapeuticsThiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) is a clinical-stage biopharmaceutical company with operations based in San Diego, CA. The Company is publicly traded on the TSX Venture Exchange and in the U.S. on the OTCQX. Thiogenesis is developing sulfur-containing prodrugs that act as precursors to previously approved thiol-active compounds, with the potential to treat serious pediatric diseases with unmet medical needs. Thiogenesis' lead product candidate, TTI-0102 has an active Phase 2 clinical trial in Mitochondrial Encephalopathy Lactic Acidosis and Stroke ("MELAS"), an IND-cleared Phase 2a clinical trial planned in Leigh syndrome spectrum, a Phase 2 clinical trial planned in pediatric Metabolic Dysfunction-Associated Steatohepatitis ("MASH") and a Phase 3 clinical trial planned in nephropathic cystinosis.For further information, please contact:Brook Riggins, Director and CFO
Email: info @vingForward-Looking StatementsThis news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as forward-looking statements) within the meaning of Canadian securities laws including, without limitation, statements with respect to the future investments by the Company. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur. Although the Company believes that the expectations reflected in the forward-looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions, or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the Company's actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTC Markets Group Inc. (OTCQX: OTCM) accepts responsibility for the adequacy or accuracy of this news release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282105
Original: Thiogenesis Therapeutics Announces Investigator-Initiated Study in Nephropathic Cystinosis and Provides Program Update

Posted on behalf of Thiogenesis Therapeutics Corp. – Today, Thiogenesis Therapeutics (TTI.v TTIPF) announced interim data from its Phase 2 (EU) clinical study of TTI-0102 in MELAS patients at Mitocon 2026 in Pisa, Italy: https://www.newsfilecorp.com/release/281290/Thiogenesis-Presents-Phase-2-EU-MELAS-Data-at-Mitocon-2026

Notably, the data was selected for the Late-Breaking News session, highlighting high scientific and clinical relevance, and confirmed that "TTI-0102 achieves meaningful biological and clinical proof-of-concept in MELAS when administered using appropriate weight-based dosing"

Posted on behalf of Thiogenesis Therapeutics Corp. – Momentum is building for Thiogenesis Therapeutics (TTI.v TTIPF) as its Phase 2 MELAS program advances, with preliminary pharmacokinetic and pharmacodynamic data for lead candidate TTI-0102 accepted as Late-Breaking News at Mitocon 2026, supporting continued development and potential expansion into additional mitochondrial disorders: Posted on behalf of Thiogenesis Therapeutics Corp. –TODAY: MELAS Abstract Accepted for Late-Breaking News Presentation at Mitocon 2026$TTI.v $TTIPF

Today, @thiogenesis announced that an abstract outlining preliminary pharmacokinetic and pharmacodynamic results from its Phase 2… https://t.co/nYKhjr7n5r pic.twitter.com/YBJPVnNK6n— Stock Master Flash (@StckMasterFlash) January 13, 2026

Posted on behalf of Thiogenesis Therapeutics Corp. – Today, Thiogenesis Therapeutics (TTI.v TTIPF) announced that an abstract outlining preliminary pharmacokinetic and pharmacodynamic results from its Phase 2 clinical trial of TTI-0102 in MELAS has been accepted as Late-Breaking News at the Mitocon Conference 2026, taking place January 23–26 in Pisa, Italy: https://www.newsfilecorp.com/release/280089/Thiogenesis-Therapeutics-MELAS-Abstract-Accepted-for-LateBreaking-News-Presentation-at-Mitocon-2026

The Phase 2 study is a randomized, double-blind, placebo-controlled, multi-center trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of oral TTI-0102 in patients with MELAS. Previously reported interim results demonstrated biological proof-of-concept and biomarker activity supporting the drug’s proposed mechanism of action.

Posted on Behalf of Thiogenesis Therapeutics Corp. – Thiogenesis Therapeutics (TTI.v TTIPF) is advancing a focused clinical strategy targeting severe mitochondrial diseases with no approved therapies, while increasing its visibility within the mitochondrial disease community: https://www.newsfilecorp.com/release/279392/Thiogenesis-to-Present-Clinical-Updates-in-MELAS-and-Leigh-Syndrome-Spectrum-at-UMDF-BenchtoBedside-Webinar

With a completed Phase 2 study in MELAS, a U.S. Phase 2a trial approaching in Leigh syndrome spectrum, and a differentiated prodrug designed to improve dosing and tolerability, TTI is steadily building clinical momentum in a space defined by high unmet need and limited therapeutic options.

Posted on behalf of Thiogenesis Therapeutics Corp. - Late in Q4 2024 Thiogenesis Therapeutics Corp. (TTI.v TTIPF) announced plans to initiate a Phase 3 pivotal clinical trial of its lead compound TTI-0102 for the treatment of nephropathic cystinosis, an inherited lysosomal storage disorder requiring lifelong cystine-depleting therapy.

The Company plans to submit an Investigational New Drug (IND) application in early 2026.

TTI-0102 is a next-generation cysteamine-based prodrug engineered to address longstanding limitations of current standard-of-care therapies including their short half-life, side effects and dosing frequency.

https://cdn.prod.website-files.com/6324f3c1cd40a857e0ea27a4/6926338767b7d1dfbc68b977_TTI%20NR%20251124%20Cystinosis%20Ph%203%20(F).pdf

Posted on Behalf of Thiogenesis Therapeutics Corp. – Following positive interim Phase 2 MELAS data and a clear regulatory path in nephropathic cystinosis, Thiogenesis Therapeutics (TTI.v TTIPF) is advancing toward pivotal Phase 3 trials with TTI-0102, its next-generation sulfur-based prodrug designed to improve tolerability and simplify dosing for severe pediatric mitochondrial and metabolic diseases: https://www.reddit.com/r/PennyStocksCanada/comments/1pf9k7f/thiogenesis_therapeutics_outlines_phase_3_plans/

Posted on Behalf of Thiogenesis Therapeutics Corp. – Marking a major step forward in rare-disease therapeutics, Thiogenesis Therapeutics (TTI.v TTIPF) recently announced plans to launch a pivotal Phase 3 trial in 2026 for TTI-0102, a next-generation cysteamine prodrug designed to transform treatment for nephropathic cystinosis, a $300M global market with urgent unmet need: Posted on Behalf of Thiogenesis Therapeutics Corp. - TODAY: @thiogenesis Announces Plans for Phase 3 Trial in Nephropathic Cystinosis$TTI.v $TTIPF

In 2026, $TTI has plans to initiate a Phase 3 clinical trial for its lead drug candidate TTI-0102 for nephropathic cystinosis.

An… https://t.co/2rcWwRq0cp pic.twitter.com/QdQ2DPzLms— Stock Master Flash (@StckMasterFlash) November 24, 2025
 
For more information on TTI and its pipeline which additionally includes clinical trials for MELAS, LSS and pediatric MASH, register to attend their presentation at the Life Sciences Virtual Investor Forum on December 11th, 2025: https://www.virtualinvestorconferences.com/wcc/eh/4814904/category/146150/december-11th-life-sciences-virtual-investor-forum

Posted on behalf of Thiogenesis Therapeutics, Corp. - Thiogenesis (TTI.v TTIPF) is developing sulfur-based prodrugs to address serious mitochondrial and metabolic disorders. With positive interim Phase 2 MELAS trial results now in hand and plans to initiate a Phase 3 clinical nephropathic cystinosis trial, TTI is entering a pivotal stage as it prepares for several major clinical milestones across its rare-disease pipeline. More here: https://www.thiogenesis.com/investors

Posted on Behalf of Thiogenesis Therapeutics Corp. – Continuing to expand its clinical footprint, Thiogenesis Therapeutics (TTI.v TTIPF) is strengthening its broader development pipeline in advancing toward a 2026 Phase 3 pivotal trial for nephropathic cystinosis: Posted on Behalf of Thiogenesis Therapeutics Corp. - TODAY: @thiogenesis Announces Plans for Phase 3 Trial in Nephropathic Cystinosis$TTI.v $TTIPF

In 2026, $TTI has plans to initiate a Phase 3 clinical trial for its lead drug candidate TTI-0102 for nephropathic cystinosis.

An… https://t.co/2rcWwRq0cp pic.twitter.com/QdQ2DPzLms— Stock Master Flash (@StckMasterFlash) November 24, 2025

This comes alongside its Phase 2 clinical trial of TTI-0102 for MELAS which recently returned positive interim results, as well as additional trials in pediatric MASH and LSS.

Posted on Behalf of Thiogenesis Therapeutics Corp. – Moving toward a major clinical milestone, Thiogenesis Therapeutics (TTI.v TTIPF) announced plans to file an IND in early 2026 and launch a Phase 3 pivotal trial for TTI-0102, a next-generation, once-daily cysteamine prodrug designed to solve long-standing tolerability and dosing challenges in nephropathic cystinosis, a rare disease market exceeding $300 million: Posted on Behalf of Thiogenesis Therapeutics Corp. - TODAY: @thiogenesis Announces Plans for Phase 3 Trial in Nephropathic Cystinosis$TTI.v $TTIPF

In 2026, $TTI has plans to initiate a Phase 3 clinical trial for its lead drug candidate TTI-0102 for nephropathic cystinosis.

An… https://t.co/2rcWwRq0cp pic.twitter.com/QdQ2DPzLms— Stock Master Flash (@StckMasterFlash) November 24, 2025

Posted on behalf of Thiogenesis Therapeutics Corp. – In 2026, Thiogenesis Therapeutics (TTI.v TTIPF) intends to launch a Phase 3 pivotal trial for TTI-0102 to improve dosing convenience and tolerability for patients with nephropathic cystinosis, a rare lysosomal disorder with a global market exceeding $300 million: Posted on Behalf of Thiogenesis Therapeutics Corp. - TODAY: @thiogenesis Announces Plans for Phase 3 Trial in Nephropathic Cystinosis$TTI.v $TTIPF

In 2026, $TTI has plans to initiate a Phase 3 clinical trial for its lead drug candidate TTI-0102 for nephropathic cystinosis.

An… https://t.co/2rcWwRq0cp pic.twitter.com/QdQ2DPzLms— Stock Master Flash (@StckMasterFlash) November 24, 2025
 
TTI expects to file its IND in early 2026, advancing a once-daily, potentially better-tolerated alternative to current cysteamine therapies.

Posted on behalf of Thiogenesis Therapeutics, Corp. - Thiogenesis Therapeutics (TTI.v TTIPF) is planning a Phase 3 trial of its lead drug for nephropathic cystinosis, a rare recessive disorder which results in progressive multi-organ damage. TTI is pursuing a streamlined regulatory pathway & aims to file an Investigational New Drug application in early 2026. More here⬇️
https://www.reddit.com/r/PennyStocksCanada/comments/1p6xyc6/thiogenesis_therapeutics_ttiv_ttipf_outlines/

Posted on behalf of Thiogenesis Therapeutics, Corp. - Yesterday, Thiogenesis Therapeutics (TTI.v TTIPF) announced plans for a Phase 3 trial of its lead drug, TTI-0102, in nephropathic cystinosis, supported by its ongoing Phase 2 trial research for MELAS. TTI plans to submit an IND application in early 2026. Full news here: https://www.newsfilecorp.com/release/275563/Thiogenesis-Therapeutics-Expands-on-Plans-for-Phase-3-Pivotal-Trial-of-TTI0102-in-Nephropathic-Cystinosis

Posted on Behalf of Thiogenesis Therapeutics Corp. - Today, Thiogenesis Therapeutics (TTI.v TTIPF) announced plans to initiate a Phase 3 pivotal clinical trial in 2026 for its lead drug candidate TTI-0102, targeting nephropathic cystinosis, a rare lysosomal storage disorder: https://www.newsfilecorp.com/release/275563/Thiogenesis-Therapeutics-Expands-on-Plans-for-Phase-3-Pivotal-Trial-of-TTI0102-in-Nephropathic-Cystinosis

With an investigational New Drug application is planned for early 2026, the trial is targeting a global patient population exceeds 2,000, representing a market of over $300 million.

Posted on behalf of Thiogenesis Therapeutics Corp. – Thiogenesis Therapeutics (TTI.v TTIPF) reported early Phase 2 data for its lead drug in MELAS, supporting its biological activity & showing biomarker improvements. Dosing issues in lighter patients will guide future trials as TTI advances programs in Leigh syndrome & nephropathic cystinosis. More⬇️
https://www.reddit.com/r/CanadaStocks/comments/1owfe79/thiogenesis_therapeutics_ttiv_ttipf_reports_early/

Posted on Behalf of Thiogenesis Therapeutics Corp. - Thiogenesis Therapeutics (TTI.v TTIPF) released positive interim data from its Phase 2 MELAS trial, showing that once-daily TTI-0102 was well tolerated in patients over 70 kg and delivered biomarker improvements consistent with its mitochondrial-restorative mechanism: TODAY: @thiogenesis Reports Positive Interim Phase 2 Results for MELAS & Expands Late-Stage Pipeline$TTI.v $TTIPF

Today, $TTI announced positive interim data for its ongoing Phase 2 clinical trial for Mitochondrial Encephalopathy, Lactic Acidosis & Stroke-like Episodes (MELAS).… https://t.co/y34WQxNpJM pic.twitter.com/ABcscxa8Uk— Stock Master Flash (@StckMasterFlash) November 4, 2025
 
With these results meeting proof-of-concept thresholds and informing dosing ahead of a planned Phase 3 study in 2026, TTI is moving into a pivotal stretch across its MELAS, Leigh syndrome, and cystinosis programs.

Thiogenesis Therapeutics (TTI.v | TTIPF): Positive Phase 2 MELAS Data Strengthens Rare-Disease Pipeline Momentum

Posted on behalf of Thiogenesis Therapeutics, Corp: Thiogenesis Therapeutics reported encouraging interim Phase 2 results for its lead compound TTI-0102 in MELAS, confirming strong safety, biomarker response, and proof-of-concept for its mitochondrial-restorative mechanism.

Phase 2 Highlights (MELAS)

• Well-tolerated in larger patients (>70 kg), consistent with Phase 1 safety data.

• Clear biomarker differentiation supports efficacy signal.

• Refined dosing underway to improve tolerance in lighter patients.

• Final 6-month data expected January 2026; pivotal Phase 3 trial to begin in Europe next year.

Pipeline Expansion

• Leigh Syndrome Spectrum – IND accepted by FDA; Phase 2 trial starts early 2026 at a major U.S. children’s hospital.

• Nephropathic Cystinosis – Phase 3 non-inferiority trial planned vs. cysteamine; aims for once-daily dosing and reduced GI side effects.

With a differentiated sulfur-based prodrug platform targeting multiple rare mitochondrial and metabolic diseases, Thiogenesis is advancing toward a pivotal year in 2026 — multiple trial initiations, final data readouts, and a clear regulatory path forward.

Learn More: https://www.reddit.com/r/CanadaStocks/comments/1ovjeiw/thiogenesis_therapeutics_tsxv_tti_otcqx_ttipf/2

Last week, Thiogenesis (TTI.v TTIPF) reported early Phase 2 MELAS trial results, showing biomarker activity, good tolerability in patients over 70kg, proof-of-concept and more. Results will help guide the planned third phase. Full news here: https://cdn.prod.website-files.com/6324f3c1cd40a857e0ea27a4/690a854c8d168110027ad857_TTI%20NR%20%20251104%20MELAS%20Ph%202%20Interim%20(F).pdf

*Posted on behalf of Thiogenesis Therapeutics Corp.

TTI.v (TTIPF) recently shared positive interim Phase 2 drug trial results for MELAS, achieving biological proof-of-concept, dose discovery & biomarker improvement. The results support progressing to Phase 3 for MELAS and TTI's Leigh Syndrome & Nephropathic Cystinosis programs. More⬇️
https://www.reddit.com/r/CanadaStocks/comments/1oqfq99/thiogenesis_therapeutics_ttiv_ttipf_reports/

*Posted on behalf of Thiogenesis Therapeutics Corp.

Earlier this week, Thiogenesis Therapeutics (TTI.v TTIPF) reported positive interim Phase 2 results for its lead candidate TTI-0102 in MELAS, a rare and devastating mitochondrial disorder, which demonstrated strong biomarker improvements and excellent tolerability, validating the drug’s antioxidant and mitochondrial-restorative mechanism: TODAY: @thiogenesis Reports Positive Interim Phase 2 Results for MELAS & Expands Late-Stage Pipeline$TTI.v $TTIPF

Today, $TTI announced positive interim data for its ongoing Phase 2 clinical trial for Mitochondrial Encephalopathy, Lactic Acidosis & Stroke-like Episodes (MELAS).… https://t.co/y34WQxNpJM pic.twitter.com/ABcscxa8Uk— Stock Master Flash (@StckMasterFlash) November 4, 2025
 
With proof-of-concept now achieved, TTI plans to advance into a pivotal Phase 3 MELAS trial in 2026—while expanding its pipeline into Leigh syndrome and nephropathic cystinosis, positioning TTI-0102 as a potential first-in-class therapy for multiple mitochondrial diseases.
 
Posted on Behalf of Thiogenesis Therapeutics Corp.

Thiogenesis Therapeutics (TTI.v TTIPF) recently shared positive interim results for its lead drug's Phase 2 MELAS trial, achieving proof-of-concept, dose discovery & biomarker improvements. The drug was well tolerated, supporting a Phase 3 MELAS trial, while TTI also advances its Leigh syndrome & nephropathic cystinosis programs. Full news here: https://cdn.prod.website-files.com/6324f3c1cd40a857e0ea27a4/690a854c8d168110027ad857_TTI%20NR%20%20251104%20MELAS%20Ph%202%20Interim%20(F).pdf

*Posted on behalf of Thiogenesis Therapeutics Corp.

Showing strong biomarker improvements and excellent tolerability, Thiogenesis Therapeutics (TTI.v TTIPF) announced positive interim Phase 2 data for its lead mitochondrial drug TTI-0102 in MELAS: TODAY: @thiogenesis Reports Positive Interim Phase 2 Results for MELAS & Expands Late-Stage Pipeline$TTI.v $TTIPF

Today, $TTI announced positive interim data for its ongoing Phase 2 clinical trial for Mitochondrial Encephalopathy, Lactic Acidosis & Stroke-like Episodes (MELAS).… https://t.co/y34WQxNpJM pic.twitter.com/ABcscxa8Uk— Stock Master Flash (@StckMasterFlash) November 4, 2025

Notably, the results validate TTI’s therapeutic approach and meet proof-of-concept thresholds, supporting progression to a pivotal Phase 3 trial in 2026.

Today, Thiogenesis Therapeutics (TTI.v TTIPF) announced positive interim data from its ongoing Phase 2 clinical trial of TTI-0102 for MELAS, demonstrating that TTI-0102 was well tolerated among patients over 70 kg and showed meaningful biomarker improvements consistent with its mitochondrial antioxidant and restorative mechanism: https://www.newsfilecorp.com/release/273012/Thiogenesis-Reports-Positive-Interim-Phase-2-Trial-Results-for-MELAS-and-Announces-Pipeline-Advancements-in-Leigh-Syndrome-and-Cystinosis
 
Notably, the findings meet proof-of-concept and dose discovery thresholds, supporting advancement into a pivotal Phase 3 study in MELAS and guiding dosing strategies across the company’s mitochondrial and metabolic programs.
 
Posted on Behalf of Thiogenesis Therapeutics Corp

Focused on accelerating clinical and regulatory milestones, Thiogenesis Therapeutics (TTI.v TTIPF) is positioning its lead compound, TTI-0102, as a differentiated therapy for rare pediatric diseases linked to oxidative and mitochondrial dysfunction: https://www.reddit.com/r/CanadaStocks/comments/1ofby45/thiogenesis_therapeutics_ttiv_ttipf_strengthens/
 
Currently TTI is advancing through multiple Phase 2 trials targeting MELAS, Leigh Syndrome Spectrum (LSS), and pediatric MASH, three serious disorders with no approved therapies. Notably, interim safety and efficacy data for the MELAS Phase 2 study is expected soon.
 
Posted on Behalf of Thiogenesis Therapeutics Corp.
 

With interim results from the MELAS study imminent and additional data expected through 2025, Thiogenesis Therapeutics (TTI.v TTIPF) is accelerating clinical momentum with three concurrent Phase 2 trials targeting rare pediatric diseases linked to oxidative stress and mitochondrial dysfunction: https://www.reddit.com/r/CanadaStocks/comments/1ofby45/thiogenesis_therapeutics_ttiv_ttipf_strengthens/

Accelerating its clinical momentum with three concurrent Phase 2 trials, key regulatory milestones, and an oversubscribed C$4.15M financing, Thiogenesis Therapeutics (TTI.v TTIPF) is advancing its lead sulfur-based drug, TTI-0102, for rare pediatric diseases driven by oxidative stress and mitochondrial dysfunction: https://www.reddit.com/r/CanadaStocks/comments/1ofby45/thiogenesis_therapeutics_ttiv_ttipf_strengthens/
 
With dosing underway in its MELAS trial in the Netherlands, FDA clearance for a U.S. Phase 2a study in Leigh Syndrome Spectrum, and EMA backing for a pediatric MASH trial in Europe, TTIis entering a pivotal year as it builds toward delivering first-in-class therapies for underserved pediatric patients.

Developing sulfur-based therapeutics for pediatric diseases caused by oxidative stress and mitochondrial dysfunction, Thiogenesis Therapeutics (TTI.v TTIPF) is enrolling patients in its Phase 2 MELAS trial and preparing to launch Phase 2 studies in Leigh Syndrome and pediatric MASH. Supported by FDA/EMA progress and C$4.15M financing, interim MELAS data are expected in October. More: https://cdn.prod.website-files.com/6324f3c1cd40a857e0ea27a4/68c8290adf9a2299a6d10024_TTI%20NR%20%20250911%20AGM%20and%20Update%20(F).pdf

Posted on behalf of Thiogenesis Therapeutics Corp.

A surge of deal-making in metabolic and rare-disease biotech is reshaping the sector, with Novo Nordisk’s $5.2B Akero Therapeutics acquisition spotlighting the value of therapies addressing mitochondrial dysfunction.

Amid this renewed momentum, Thiogenesis Therapeutics (TTI.v TTIPF) is carving out a niche with its next-generation cysteamine-based prodrugs designed to restore cellular energy balance: https://www.reddit.com/r/PennyStocksCanada/comments/1o3fffh/thiogenesis_therapeutics_ttiv_ttipf_biotech/

Backed by extended IP to 2038, a strong treasury, and three Phase 2 programs advancing in MELAS, Leigh Syndrome, and pediatric MASH, Thiogenesis is positioning itself at the intersection of science, scarcity, and strategic interest.

Posted on Behalf of Thiogenesis Therapeutics Corp.

Big pharma’s appetite for metabolic and mitochondrial therapies is accelerating with Novo Nordisk’s $5.2B acquisition of Akero Therapeutics highlighting surging interest in MASH and oxidative stress–linked diseases,

Notably, these are the same biological pathways targeted by Thiogenesis Therapeutics (TTI.v TTIPF).

With three Phase 2 programs underway and IP protection through 2038, TTI is emerging as a small-cap biotech positioned squarely in the path of growing industry consolidation. More Info: https://www.reddit.com/r/PennyStocksCanada/comments/1o3fffh/thiogenesis_therapeutics_ttiv_ttipf_biotech/

Biotech is heating up while Thiogenesis (TTI.v TTIPF) advances its lead drug in Phase 2 programs for several mitochondrial/metabolic disorders, with a trial for MELAS already underway. More on TTI’s positioning & big sector news like Akero’s $5.2B buyout & SHRX’s 107% surge here 💊🩺💥⬇️
https://www.reddit.com/r/PennyStocksCanada/comments/1o3fffh/thiogenesis_therapeutics_ttiv_ttipf_biotech/

As Novo Nordisk’s $5.2B buyout of Akero Therapeutics (AKRO) ignites a new wave of interest in MASH and mitochondrial-linked diseases, Thiogenesis Therapeutics (TTI.v TTIPF) is emerging as a small-cap contender with three Phase 2 programs targeting MELAS, Leigh Syndrome, and pediatric MASH, leveraging its cysteamine-based platform to tackle oxidative and mitochondrial dysfunction at the root of metabolic disease: Large-cap pharma’s renewed buying spree in metabolic and genetic disease continues, with Novo Nordisk’s $5.2B acquisition of $AKRO, underscoring surging interest in MASH and mitochondrial-linked disorders. $TTI.v $TTIPF

Notably, $AKRO's EFX targets mechanisms tied to oxidative… https://t.co/vwu3JjDWgQ— Stock Master Flash (@StckMasterFlash) October 15, 2025

Large-cap pharma’s renewed buying spree in metabolic and genetic disease continues, with Novo Nordisk’s $5.2B acquisition of Akero Therapeutics (AKRO) underscoring surging interest in MASH and mitochondrial-linked disorders.

Akero’s efruxifermin (EFX) targets mechanisms tied to oxidative stress, similar to Thiogenesis Therapeutics’ (TTI.v TTIPF) cysteamine-based platform addressing oxidative and mitochondrial dysfunction across rare and metabolic diseases: https://www.reddit.com/r/PennyStocksCanada/comments/1o3fffh/thiogenesis_therapeutics_ttiv_ttipf_biotech/

With three Phase 2 programs in MELAS, Leigh Syndrome, and pediatric MASH, Thiogenesis offers diversified exposure to these fast-moving therapeutic areas.

#BioTech @thiogenesis $TTI $TTI.v $TTIPF

Another major buyout in the obesity & liver disease space — Novo Nordisk acquiring $AKRO for up to $5.2Bhttps://t.co/ZX0qdFssRG

Notably, $AKRO's drug treats compensated cirrhosis due to MASH, the same disease $TTI is addressing through… pic.twitter.com/QVzI5UizN4— The TSX Dude (@TheTSXDude) October 10, 2025

Advancing its Phase 2 trial of TTI-0102 for MELAS ahead of interim data expected Q3 2025, Thiogenesis Therapeutics (TTI.v TTIPF) is entering a pivotal period backed by strong management, multiple near-term catalysts, and a differentiated prodrug platform targeting rare mitochondrial diseases.

With Executive Chairman Chris Starr, also Chair of Monopar Therapeutics (Nasdaq: MNPR). bringing proven biotech leadership, TTI is advancing toward key readouts and potential revaluation in the rare disease space.

More Info: Strategic Leadership Spotlight - @thiogenesis $TTI.v $TTIPF

Advancing a late-stage pipeline across orphan & pediatric diseases with no approved therapies, $TTI is led by its novel prodrug platform, currently in a Phase 2 EU clinical trial with interim data expected in Q3 2025.… https://t.co/jaWWqJcUD1— Stock Master Flash (@StckMasterFlash) October 4, 2025

Up over 7% with above average volume, Thiogenesis Therapeutics (TTI.v TTIPF) is advanceing toward key Phase 2 readouts with strong leadership behind its momentum, including Executive Chairman Chris Starr, also Chair of Monopar Therapeutics (Nasdaq: MNPR), whose recent financing success underscores his ability to steer biotech companies through value-defining milestones.

With interim MELAS data expected Q3 2025 and additional trials in Leigh Syndrome and Pediatric MASH on deck, TTI is entering a catalyst-rich period guided by proven expertise and a focused late-stage pipeline: Strategic Leadership Spotlight - @thiogenesis $TTI.v $TTIPF

Advancing a late-stage pipeline across orphan & pediatric diseases with no approved therapies, $TTI is led by its novel prodrug platform, currently in a Phase 2 EU clinical trial with interim data expected in Q3 2025.… https://t.co/jaWWqJcUD1— Stock Master Flash (@StckMasterFlash) October 4, 2025

Entering a catalyst-rich phase with Phase 2 MELAS data expected in Q3 2025, Thiogenesis Therapeutics (TTI.v TTIPF) is advancing a late-stage orphan and pediatric pipeline under the guidance of Executive Chairman Chris Starr, whose leadership at Monopar Therapeutics (Nasdaq: MNPR) recently helped drive a successful financing and strong market response: Strategic Leadership Spotlight - @thiogenesis $TTI.v $TTIPF

Advancing a late-stage pipeline across orphan & pediatric diseases with no approved therapies, $TTI is led by its novel prodrug platform, currently in a Phase 2 EU clinical trial with interim data expected in Q3 2025.… https://t.co/jaWWqJcUD1— Stock Master Flash (@StckMasterFlash) October 4, 2025

Advancing a late-stage pipeline across orphan and pediatric diseases with no approved therapies, Thiogenesis Therapeutics (TTI.v TTIPF) is led by its novel prodrug platform TTI-0102, currently in a Phase 2 EU clinical trial for MELAS with interim data expected in Q3 2025.

A key aspect often overlooked is the company’s leadership depth. Chris Starr, Executive Chairman of Thiogenesis, also serves as Chairman of Monopar Therapeutics (Nasdaq: MNPR), who recently completed a successful financing round that saw a strong market reaction, underscoring Starr’s track record in guiding biotech ventures through critical inflection points.

For more information, refer to this company breakdown: SLIDE DECK BREAKDOWN - @thiogenesis $TTI.v $TTIPF

Advancing a late-stage pipeline targeting high-value orphan & pediatric markets with no approved therapies, $TTI is positioned to deliver near-term clinical catalysts and long-term value creation.

Slide Summary Thread🔽 https://t.co/CxM9FKPI5W pic.twitter.com/Al9fRIWxhL— Stock Master Flash (@StckMasterFlash) September 9, 2025

The biopharm co. Thiogenesis Therapeutics (TTI.v TTIPF) is advancing a Phase 2 MELAS trial (with interim data expected this month) while preparing additional Phase 2 programs to test its lead drug against 2 other serious pediatric diseases with no approved therapies. Full DD & news breakdown here⬇️
https://www.reddit.com/r/PennyStocksCanada/comments/1nurin8/thiogenesis_therapeutics_ttiv_ttipf_is_on_track/

Thiogenesis Therapeutics (TTI.v TTIPF) is on track to execute three Phase 2 programs for its lead candidate TTI-0102, supported by FDA and EMA progress and a recent C$4.15M in financing. Interim data from its MELAS trial is expected in October. More: https://cdn.prod.website-files.com/6324f3c1cd40a857e0ea27a4/68c8290adf9a2299a6d10024_TTI%20NR%20%20250911%20AGM%20and%20Update%20(F).pdf

*Posted on behalf of Thiogenesis Therapeutics Corp.

Gearing up for a potentially transformative moment as interim results approach in its Phase 2 MELAS trial of TTI-0102, Thiogenesis Therapeutics (TTI.v TTIPF) is evaluating safety, tolerability, pharmacokinetics, and early efficacy over six months in the randomized, double-blind, placebo-controlled trial: SLIDE DECK BREAKDOWN - @thiogenesis $TTI.v $TTIPF

Advancing a late-stage pipeline targeting high-value orphan & pediatric markets with no approved therapies, $TTI is positioned to deliver near-term clinical catalysts and long-term value creation.

Slide Summary Thread🔽 https://t.co/CxM9FKPI5W pic.twitter.com/Al9fRIWxhL— Stock Master Flash (@StckMasterFlash) September 9, 2025

With MELAS being a rare mitochondrial disorder lacking approved treatments, positive interim data could serve as a major catalyst with TTI-0102 potentially emerging as a frontrunner in the mitochondrial disease space.

Targeting a late-stage pipeline in orphan & pediatric diseases with no approved therapies, Thiogenesis Therapeutics (TTI.v TTIPF) has Phase 2 MELAS data due Q3 2025, multiple indications advancing, and a ~C$39M market cap, offering rare-disease upside: SLIDE DECK BREAKDOWN - @thiogenesis $TTI.v $TTIPF

Advancing a late-stage pipeline targeting high-value orphan & pediatric markets with no approved therapies, $TTI is positioned to deliver near-term clinical catalysts and long-term value creation.

Slide Summary Thread🔽 https://t.co/CxM9FKPI5W pic.twitter.com/Al9fRIWxhL— Stock Master Flash (@StckMasterFlash) September 9, 2025

Clinical-stage biotech company,Thiogenesis Therapeutics (TTI.v TTIPF) is a advancing a late-stage pipeline across orphan and pediatric diseases with no approved therapies with its lead compound, showing improved tolerability and higher dosing potential in Phase 1: SLIDE DECK BREAKDOWN - @thiogenesis $TTI.v $TTIPF

Advancing a late-stage pipeline targeting high-value orphan & pediatric markets with no approved therapies, $TTI is positioned to deliver near-term clinical catalysts and long-term value creation.

Slide Summary Thread🔽 https://t.co/CxM9FKPI5W pic.twitter.com/Al9fRIWxhL— Stock Master Flash (@StckMasterFlash) September 9, 2025

Now in a Phase 2 EU trial for MELAS, with interim data expected Q3 2025, TTI's he pipeline extends into Leigh Syndrome (Phase 2a start Q1 2026), Pediatric MASH (Phase 2 planned 2025), and Rett Syndrome (Phase 2/3 filing in 2026).

Thiogenesis (TTI.v TTIPF) is a clinical-stage biotech company developing sulfur-based treatments for oxidative stress/inflammation in mitochondrial disease. Now in Phase 2, its lead drug has shown high-dose tolerability & is being ain MELAS, Leigh syndrome & other pediatric conditions. More⬇️
https://www.reddit.com/r/PennyStocksCanada/comments/1nlibev/thiogenesis_therapeutics_inc_ttiv_ttipf_advancing/